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Toll-like receptorAbstract Systemic sclerosis (SSc) is a multisystem fibrotic and autoimmune disease. Both genetic
and epigenetic elements mediate SSc pathophysiology. This review summarizes the role of one
epigenetic element, known as microRNAs (miRNAs), involved in different signaling pathways of
SSc pathogenesis. The expression of key components in transforming growth factor-b (TGF-b)
signaling pathway has been found to be regulated by miRNAs both upstream and downstream
of TGF-b. We are specifically interested in the pathway components upstream of TGF-b, while
miRNAs in other signaling pathways have not been extensively studied. The emerging role of
miRNAs in vasculopathy of SSc suggests a promising new direction for future investigation. Elu-
cidation of the regulatory role of miRNAs in the expression of signaling factors may facilitate
the discovery of novel biomarkers in SSc and improve the understanding and treatment of this
disease.Introduction
Systemic sclerosis (SSc) is a multisystem fibrotic and autoim-
mune disease mediated by complex interactions between
endothelial damage, non-infective inflammation or autoimmu-
nity, and fibroblast to myofibroblast transition [1,2].
Endothelial damage may be the primary event in the pathogen-esis of SSc, resulting in narrowing of the capillary lumen and
loss of the microvasculature, while fibrosis appears to be the
final consequence [2–6].
The immune system participates in the pathogenesis of SSc.
Adaptive immune cells, particularly T cells, which were found
to be adjacent to myofibroblasts in affected tissues of SSc
patients, are self-intolerant, and secrete pro-inflammatory and
fibrogenic cytokines [1]. Furthermore, T helper (Th) cell balance
is biased toward Th2 in SSc patients. There is a higher level of
Th2 cytokines in the dermal fibroblasts, such as interleukin
(IL)-13, which could induce collagen expression [1–3,5,6]. B cells
are not generally prominent in SSc lesions but are generally acti-
vated, resulting in the autoimmune response [2,3]. Monocytes of
the innate immune system appear to initially infiltrate the SSc
lesions, differentiate into dendritic cells upon lesional stimula-
tion, and generate profibrotic cytokines [1].nces and
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pathogenesis. Soluble mediators generated by the endothelial
and inflammatory cells suggest inappropriate activation of
fibroblasts, resulting in the secretion of extracellular matrix
(ECM) macromolecules, growth factors, and cytokines, as well
as transdifferentiation into contractile myofibroblasts [2–8].
Myofibroblasts are effector cells in SSc fibrosis, which either
produce excessive fibrillar collagens in the accumulated ECMs
or disrupt the normal tissue architecture, leading to the loss of
organ function [1,2,9].
Compared to genetic factors, epigenetics plays a much lar-
ger role in SSc pathogenesis [10–14]. Epigenetic processes are
adaptive mechanisms responding to environmental stimuli.
These include DNA methylation (of cytosine at position C5
at CpG dinucleotides), histone modifications (lysine acetyla-
tion, lysine and arginine methylation, serine and threonine
phosphorylation, lysine ubiquitination and sumoylation), and
RNA interference (including gene silencing induced by micro-
RNAs, long non-coding RNAs, RNA modifications, etc.).
Studies suggest that these aforementioned epigenetic processes
do occur in SSc pathogenesis [10–13,15].
MicroRNAs (miRNAs) are small non-coding RNAs
(ncRNAs) approximately 21 nucleotides in length that are par-
tially or completely complementary to and bind with mRNAs,
leading to mRNA degradation or reduced mRNA translation.
miRNAs account for 1%–2% of the human genome [10]; they
are transcribed as precursors and further cleaved into mature
miRNAs by ribonuclease Drosha/DGCR-8, and Dicer in the
nucleus and cytoplasm [10]. Differentially-expressed miRNAs
identified in SSc target both inflammation and fibrosis
[10,14]. Functional studies suggest that miRNAs mainly mod-
ulate fibrosis-related genes encoding collagens, metallopepti-
dases, and integrins [11,16–20].
Differentially-expressed miRNA profile in SSc
Downregulated miRNAs
Downregulated miRNAs primarily serve as inhibitory
miRNAs for fibrotic genes. MiR-29a and miR-29b have been
identified as targets for downregulation in dermal fibroblasts
from SSc patients and bleomycin-induced SSc mice [21,22]
and, interestingly, in hair samples from SSc patients [23].
However, such downregulation was not observed in the serum
of SSc patients [24]. Numerous studies have supported the role
of miR-29s in SSc pulmonary fibrosis [25,26] and in phalangeal
contracture [23]. miR-196a is also reportedly downregulated in
dermal fibroblasts and serum of SSc patients [27,28].
Moreover, miR-196a levels in hair shafts are stably decreased
in SSc patients, indicating that this miRNA can be used as a
new biomarker for SSc diagnosis [29]. Similarly, miR-150
was downregulated in dermal fibroblasts and serum of SSc
patients as well, and its level was negatively correlated with
disease severity [30]. Let-7a is another miRNA that is down-
regulated miRNA in both dermal fibroblasts and serum of
SSc patients [31]. Additional miRNAs downregulated in SSc
dermal fibroblasts or microvascular endothelial cells (MVECs)
include miR-129-5p, miR-30b, miR-145, miR-193b, and
miR-152 [22,32,33]. Among them, levels of miR-30b wereinversely correlated with modified Rodnan skin scores of these
patients, reflecting disease severity [33]. Other than those,
downregulation of miR-223 has been demonstrated in SSc
plasma samples [34].
Upregulated miRNAs
The upregulated miRNAs mostly inhibit anti-fibrotic genes.
Our group found that miR-21 was upregulated in dermal
fibroblasts and skin tissues of SSc patients based on microar-
ray analysis; miR-130b, miR-146, and miR-503, among others,
were also upregulated in skin tissues [22]. Furthermore, the ele-
vated expression of miR-146 in skin samples may be correlated
with the occurrence of vascular abnormality in SSc, such as
telangiectasia [35]. The elevated miR-92a levels in serum and
in dermal fibroblasts of SSc patients were also correlated with
the presence of telangiectasia but not with disease activity [36].
miRNAs with conflicting findings
There are some miRNAs with conflicting findings in their
expression levels in SSc. Their roles in SSc pathogenesis need
to be further investigated. For example, miR-7 targets fibrotic
genes, but is upregulated in SSc. One microarray analysis indi-
cated that the miR-7 level was upregulated in SSc fibroblasts,
suppressing fibrotic processes. This was suggested to be a neg-
ative feedback loop against excessive fibrogenesis [37] but fail
to overcome the pathogenic fibrosis in SSc. Another study
reported that miR-7 level was downregulated in localized scle-
roderma dermis but not in SSc dermis, suggesting that miR-7
may also target unknown anti-fibrotic pathways and act as a
modulator in both sides of fibrosis regulation [38].
Similarly, conflicting findings were also documented for
miR-142-3p. One report demonstrated significant upregulation
of miR-142-3p in the serum of SSc patients, particularly in
those with a short lingual frenulum [39]. This finding suggests
a possible negative feedback effect of miR-142-3p on over-
activation of tumor growth factor-b (TGF-b) in SSc dermal
fibroblasts. However, another report suggested that level of
this anti-fibrotic miRNA was downregulated in the serum of
SSc patients, in comparison to systemic lupus erythematosus
patients and healthy controls [34]. These findings suggest that
miR-142-3p may be another miRNA with dual effects in fibro-
sis regulation.
miRNAs in TGF-b signaling pathway in SSc
TGF-b signaling in SSc
The TGF-b pathway is a critical signaling pathway in fibrosis,
particularly SSc. TGF-b is secreted as a latent precursor and
requires proteolytic cleavage for activation by integrins,
thrombospondin-1, or reactive oxygen species [1,4,6,8]. For
TGF-b pathway, the downstream activation of the canonical
SMAD pathway (SMAD2/3), STAT3, and other noncanonical
pathways (e.g., SMAD1, c-Abl, EGR1, and ERK1/2) is
associated with the profibrotic response and induction of
myofibroblast differentiation [1,2,4,6–9]. In SSc fibroblasts,
multiple abnormalities occur in the SMAD signaling path-
ways. These include elevated expression or phosphorylation
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coactivator p300, elevated levels of p300, and defective func-
tion of SMAD7, the endogenous inhibitor of SMAD signaling
[8,40,41]. Activation of non-canonical signaling pathways may
occur via autocrine TGF-b stimulation, including SMAD1,
AKT, and ERK1/ERK2, contributing to the maintenance of
the activated fibroblast phenotype even in the absence of
exogenous stimuli [4,8]. TGF-b further upregulates the
expression of connective-tissue growth factor (CTGF) [6],
which possesses profibrotic activities similar to TGF-b, and
downregulates the levels of IL-17A receptor, thus inhibiting
the suppressive impact of IL-17A on CTGF and collagen
expression [32]. Interestingly, myofibroblast contraction can
mechanically activate the TGF-b precursor, reinforcing this
loop [1,3,9].
miRNAs targeting factors downstream of TGF-b
The miR-29 family members, including miR-29a and miR-29b,
are the most important miRNAs involved in TGF-b signaling
and collagen production [21,42]. Recently, TGF-b activated
kinase 1 (TAK1)-binding protein 1 (TAB1) was defined as a
new miR-29a target. Upregulation of TAB1 expression was
found to trigger the production of the tissue inhibitor of
metalloproteinase-1 (TIMP-1) and inhibition of matrix metal-
loproteinase (MMP)-1, leading to reduced collagen degrada-
tion [43]. TGF-b, platelet-derived growth factor (PDGF),
and IL-4 have been identified as upstream modulators of
miR-29 members in SSc, which inhibit transcription of miR-
29 members [21,42,44]. miR-29a expression is downregulated
by SMAD3 via TGF-b/SMAD signaling in SSc, which has
been confirmed by protection against bleomycin or TGF-b1-
induced loss of miR-29a along with fibrosis in SMAD3-null
models [25].
A group of miRNAs in SSc pathogenesis directly targets
collagen genes and is inhibited by upstream TGF-b signaling.
For example, miR-196a is negatively modulated by TGF-b
and targets transcripts encoding collagen in fibroblasts, partic-
ularly collagen 1 and collagen 3 [27,28,45]. Additionally, let-7a
affected the expression of type I collagen as an upstream mod-
ulator and in turn was downregulated by active TGF-b signal-
ing [31]. miR-129-5p expression is downregulated by TGF-b
signaling by suppressing IL-17A signaling, thus leading to
increased a1(I) collagen expression [32].
Another group of miRNAs targets the downstream factors
of the TGF-b signaling pathway, such as SMADs. Our group
found that the upregulated miR-21 in SSc targeted SMAD7,
which was verified using a reporter gene assay [22,46]. As
described above, SMAD7 is an endogenous inhibitor of
SMAD signaling. Therefore, downregulation of SMAD7 by
miR-21 leads to increased SMAD signaling followed by fibro-
sis. miR-21 is thought to be upregulated by TGF-b in SSc
pathogenesis [22]. There are other miRNAs that target
SMADs downstream of TGF-b. The putative targets of
miR-145, miR-146, and miR-503 are SMAD3, SMAD4, and
SMAD7, respectively, which requires further verification [22].
miRNA targeting factors upstream of TGF-b
The major upstream factors of TGF-b targeted by miRNAs
include integrins, which are activators of TGF-b precursors.miR-150 targets integrin-b3, a key upstream event in TGF-b
activation, followed by phosphorylation of SMAD3 and accu-
mulation of type I collagen [30]. Downregulation of miR-150
in SSc may occur through an epigenetic mechanism and
involves DNA methylation [30]. Protein expression of laminin
and integrin was also significantly elevated in miR-29-
knockdown fibroblasts, similar to collagen genes [26].
Therefore, miR-29 may target integrin genes, suggesting that
it is also an upstream modulator of TGF-b activation. miR-
142-3p is one of the miRNAs regulating the expression of
integrin aV [39]. Decreased expression of miR-142-3p leads
to overexpression of integrin aV and consequently TGF-b
over-activation in SSc dermal fibroblasts [47,48].
miRNAs in vasculopathy signaling pathways in SSc
The uPA signaling pathway
Urokinase-type plasminogen activator (uPA) and its receptor
(uPAR) pathway in vasculopathy facilitate neointimal growth
and vascular remodeling, as well as fibrosis by enhancing
matrix degradation [49,50]. Recent studies have confirmed that
impaired uPA/uPAR signaling caused by inactivation and
cleavage of uPARs in MVECs contributed to poor angiogene-
sis in SSc pathogenesis [51,52]. However, uPA levels were
shown to be elevated in SSc dermal fibroblasts in response to
TGF-b stimulation [51,52]. The enhanced uPA signaling
induced cell proliferation and inhibited apoptosis of human
pulmonary artery smooth muscle cells via uPAR-sparing
pathways, leading to proliferative vasculopathy in SSc
[51,52]. Furthermore, Iwamoto et al. [53] find out that
miR-193b targets uPA and is downregulated in SSc dermal
fibroblasts, possibly accounting for the upregulation of uPA
expression. Thus, miR-193b downregulation probably con-
tributes to proliferative vasculopathy in SSc.
DNA methyltransferase 1
Evidence suggests that miR-152 targeting of DNA methyl-
transferase 1 (DNMT1) leads to decreased global DNA methy-
lation, including the genes encoding the bone morphogenic
protein (BMP) receptor II and nitric oxide synthetase (NOS)
[54]. Downregulation of miR-152 and the resulting gene hyper-
methylation in SSc MVECs lead to endothelial cell (EC) apop-
tosis, vasoconstriction, inflammatory cell infiltration, and
ultimately fibroblast activation [54]. The relationship between
miR-152 and the signal molecules secreted by damaged ECs
in SSc requires further analysis.
miRNAs in TLR signaling in SSc
TLR signaling in SSc
The role of innate immune signaling and Toll-like receptors
(TLRs), particularly TLR4, signaling in SSc fibrosis have been
examined in recent decades [55]. Endogenous ligands for TLRs
in SSc include ECMmolecules (e.g., alternatively-spliced fibro-
nectins, abbreviated as Fn-EDA, induced by TGF-b in normal
fibroblasts), cellular stress proteins (high-mobility group pro-
tein B1, abbreviated as HMGB1, and HSP60), and nucleic-
acid-containing immune complexes [4,7,55]. TLR signaling,
particularly TLR4, results in inflammatory cell infiltration, B
cell activation, polarization toward a Th2/Th17 response,
activation of nuclear factor kappa beta (NF-jB), elevated
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vation of TGF-b downstream canonical SMAD signaling,
and pathological angiogenesis in SSc [55–60]. The expression
of TLR4, its ligands (e.g., S100A8/A9), and its co-receptors
(MD2 and CD14) was elevated in the plasma, lesional skin,
and lung biopsies of SSc patients [55,58,61]. TLR8 on SSc
monocytes recognizes immune complexes against self-DNA/
RNA to trigger activation of NF-jB and downstream genes,
such as interferon [1,55]. This leads to the production of profi-
brotic TIMP-1 and enhances ECM deposition via an MMP
blockade in an IL-1R-associated kinase (IRAK)-dependent
mechanism [1,55,57,62]. Additional evidence suggests that
TLR2, TLR3, TLR5, TLR7, TLR9, and TLR10 mediate SSc
pathogenesis, although their involvement remains controver-
sial [4,55,57,63–66].
miRNAs and TLR signaling pathway
The evidence is very limited for direct regulation of miRNAs in
TLR signalings. miR-29 is the only one definitely reported in
the literature so far. Activated TLR4 signaling targets antifi-
brotic miR-29, leading to its downregulation along with
SMAD2/3 upregulation [55,58]. Both of these downstream sig-
nals contribute to fibrotic processes in SSc. TLR signaling
pathway is very important in SSc pathogenesis and displays
close interaction with TGF-b downstream signaling. As men-
tioned above, a large number of miRNAs participated in
TGF-b downstream signaling pathways. These miRNAs target
the common downstream components in both pathways and
thus may also influence TLR downstream signaling as well.
Epigenetic regulation of Wnt signaling in SSc
The Wnt signaling pathway is involved in SSc pathogenesis,
particularly fibrosis, in addition to TGF-b signaling. Binding
of Wnt to the surface receptor frizzled stabilizes and activates
b-catenin in the canonical TGF-b pathway. The activated
b-catenin translocates to the nucleus and activates target genes
in TGF-b signaling [1,7,8]. In addition to the induction of
TGF-b signaling, nuclear b-catenin also activates the myofi-
broblast transition [1,3,4,8,67,68]. In skin biopsies of SSc
patients and scleroderma mice, evidence supports
constitutively-activated Wnt-b-catenin signaling (Wnt1,
Wnt3a, and Wnt10b) and elevated expression of Wnt2, Wnt9a,
Wnt11, and secreted frizzled-related proteins (SFRP)
[8,67–70]. Epigenetic suppression of Wnt antagonists occurs
in the fibroblasts and peripheral blood mononuclear cells of
SSc patients [71,72]. However, there is still no supporting evi-
dence for the involvement of miRNAs in this signaling path-
way in SSc. Therefore, further investigation is required.
miRNAs in other signaling pathways in SSc
The precise target of miR-92a has not been identified.
However, evidence suggests that miR-92a downregulates the
protein expression of MMP-1, an enzyme that degrades the
ECM [36]. TGF-b may be an upstream modulator of miR-
92a [36]. The levels of miR-92a are significantly elevated in
SSc, leading to MMP-1 downregulation followed by reduced
ECM degradation. In our previous study, the target of
miR-130b was found to be peroxisome proliferator-activatedreceptors (PPAR), which disrupt TGF-b signaling through
an anti-fibrotic signaling mechanism [73,74]. Upregulation of
miR-130b expression in SSc may result in defective PPAR
expression and ultimately enhance TGF-b signaling and
fibrosis-related gene expression. Expression of miR-130b is
upregulated by TGF-b via the TGF-b/SMAD pathway,
suggesting a positive feedback route for over-activation of
TGF-b signaling [73].
Another signaling pathway, platelet-derived growth factor
(PDGF) pathway, is related to SSc pathogenesis and is the tar-
get for some miRNAs. Transfection of miR-30b repressed the
expression of PDGF receptor (PDGFR)-b in dermal fibrob-
lasts by directly binding to the PDGFRB mRNA, which was
verified using luciferase reporter gene assays [33]. Therefore,
miR-30b likely mediates SSc pathogenesis via the PDGF
signaling pathway.
As described above, miR-196a targets genes coding for col-
lagens. The possible feedback to excessive collagen accumula-
tion is mediated via the discoidin domain receptor 2 (DDR2)-
miR-196a pathway [75]. In SSc fibroblasts, this pathway
may be impaired, resulting in the abnormal accumulation of
ECMs [75].
For miR-7, it is an upstream downregulator of type I colla-
gen mRNAs [37,38]. miR-7 level was upregulated in SSc
fibroblasts, showing a negative feedback effect against fibrosis
due to its downregulated suppressor, intracellular TSP-2
[37,38]. However, expression of miR-7 was downregulated in
localized scleroderma dermis, suggesting modulation via
unknown pathways, leading to overexpression of collagens in
SSc pathogenesis [38].Discussion
SSc phenotypes display marked heterogeneity and a complex
interplay between different pathogenic processes, including
vasculopathy, autoimmunity, and fibrosis. The key challenge
in clinical practice is the discovery of new biomarkers that
can be used for better diagnosis and disease classification.
Notably, miRNAs are involved in different signaling pathways
of SSc and regulate its pathophysiology, suggesting their
promising role as biomarkers of SSc.
Among the miRNAs that mediate SSc pathogenesis via dif-
ferent signaling pathways (Table 1), TGF-b signaling is the
most important in SSc fibrosis and the involvement of miR-
NAs in this pathway has been extensively studied (Figure 1).
The mechanisms of other signaling pathways and miRNAs
remain unclear. As evidence supporting miRNA functioning
in vasculopathy of SSc accumulates, we hypothesize that this
primary event in SSc pathogenesis is controlled by a complex
miRNA network. Therefore, several unresolved issues regard-
ing miRNA regulation and the roles of miRNAs in different
signaling pathways should be examined to gain a better under-
standing of SSc pathogenesis.
miRNAs have recently emerged as promising biomarkers of
various autoimmune disorders, such as systemic lupus erythe-
matosus, rheumatoid arthritis, type 1 diabetes mellitus, and
multiple sclerosis [76]. The roles of miRNAs overlap in differ-
ent autoimmune disorders, suggesting common pathways in
their pathogenesis. Therefore, some miRNAs mediating SSc
pathogenesis are summarized in this review, including miR-
21 and miR-146, among others [76]. Expression of miR-21 is
Table 1 miRNA expression in systemic sclerosis
miRNA Expression Target genes Refs.
TGF-b downstream signaling
miR-29a Downregulated COL1A1, COL3A1 [21]
miR-29b Downregulated COL1A1 [42]
miR-196a Downregulated COL1A1, COL3A1 [45]
let-7a Downregulated COL1A1, COL1A2 [31]
miR-129-5p Downregulated COL1A1 [32]
miR-21 Upregulated SMAD7 [22,46]
miR-145 Downregulated SMAD3 [22]
miR-146 Upregulated SMAD4 [22]
miR-503 Upregulated SMAD7 [22]
TGF-b upstream regulator
miR-150 Downregulated ITGB3 [30]
miR-142-3p Controversial ITGAV [39]
miR-29 Downregulated Laminin genes and integrin genes [26]
uPA signaling in MVECs
miR-193b Downregulated PLAU [53]
Hypermethylation in MVECs
miR-152 Downregulated DNMT1 [54]
TLR signaling
miR-29 Downregulated COL1A1, COL3A1 [21]
PDGF signaling
miR-30b Downregulated PDGFRB [33]
TSP-2 signaling
miR-7 Controversial COL1A2 [38]
Other signaling
miR-92a Upregulated MMP1 [36]
miR-130b Upregulated PPARG [73,74]
Figure 1 miRNA participation in TGF-b signaling pathway in systemic sclerosis
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T cells [77]. However, miRNAs, which may share similar path-
ways, are differentially regulated based on the clinical hetero-
geneity of individual disorders. For instance, SLE patients had
reduced miR-146a levels [78], whereas SSc patients showed an
upregulated expression of miR-146a [22], possibly because of
the Th2 bias phenomenon in SSc pathogenesis. miR-146a in
PBMCs of the Chinese lupus population suppresses the inter-
feron pathway [79] and the Th1 response [80].
In this review, we summarized miRNAs that have been
reported to be involved in SSc pathogenic pathways to high-
light their role in the pathogenesis of this disease and to under-
stand the interaction of different signaling pathways in the
same disease. For SSc, different phenotypes have characteristic
features in signaling activation, which could be partially attrib-
uted to miRNA interference. Therefore, miRNAs can be
potential biomarkers for early discovery of onsets of severe
phenotypes. The miRNA signatures are both uniform (in
terms of similar signaling pathways involved) and heteroge-
neous (in terms of individual performance of these pathways
in different diseases) for different autoimmune diseases, there-
fore they are promising biomarkers for differential diagnosis of
these diseases. However, many signaling pathways in SSc
pathogenesis have not been clearly described in terms of
miRNA interference. Are there new miRNA players involved
in the regulation of these pathways? Are these miRNAs asso-
ciated with different SSc phenotypes? Further efforts are
needed to answer these questions.
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